<DOC>
	<DOCNO>NCT00802841</DOCNO>
	<brief_summary>There available data clinical benefit dose escalation patient suboptimal response imatinib , patient may still improve response continuation therapy standard dose show IRIS trial 5 year follow-up . However , data yet regard potential benefit use nilotinib group patient suboptimal response . In study , efficacy nilotinib 400mg BID compare imatinib 600mg QD .</brief_summary>
	<brief_title>Randomized Phase Lll Study Imatinib Dose Optimization v Nilotinib CML Patients With Suboptimal Response Imatinib</brief_title>
	<detailed_description>The comparative efficacy imatinib dose escalation ( 600 mg QD ) nilotinib ( 400 mg BID ) , term CCyR 6 month , patient CML chronic phase suboptimal response imatinib standard dose determine .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female ≥ 18 year old ; 2 . ECOG 0 , 1 , 2 ; 3 . Ph+ CML CP define : &lt; 15 % blast peripheral blood bone marrow ; &lt; 30 % blast + promyelocytes peripheral blood bone marrow ; &lt; 20 % basophils peripheral blood ; •≥100x109/L ( ≥ 100,000/mm3 ) platelet ; evidence extramedullary leukemia involvement , exception hepatosplenomegaly ; 4 . SoR 400 mg imatinib , define ( min 20 metaphase ) : No cytogenetic response ≥ 3 &lt; 6 month ( &gt; 95 % Ph+ metaphases ) ; No PCyR ≥ 6 &lt; 12 month ( 36 95 % Ph+ metaphases bone marrow ) ; No CCyR ≥ 12 &lt; 18 month ( 1 35 % Ph+ metaphases bone marrow ) ; Confirmation SoR FISH allow BMK do outside screen window 4 wks . 5 . 400mg/daily imatinib ( high dos ) least 3months long 18 month ; 6 . Previous use IFN , take prior imatinib treatment , allow maximum 90 day unless reason switch IFN imatinib intolerance . 7 . Parameters must present : Creatinine &lt; 2.0 X ULN Total bilirubin &lt; 1.5 X ULN ( &lt; 3.0 X ULN related disease ) ; SGOT SGPT &lt; 2.5 X ULN ; Serum lipase ≤1.5 X ULN ; Alkaline phosphatase ≤2.5 X ULN Serum potassium , phosphorus , magnesium calcium ≥ LLN correct WNL supplement prior first dose study drug ; 8 . Written inform consent prior study procedure perform . Exclusion criterion : 1 . Prior accelerate phase include clonal evolution blast crisis CML ; 2 . Prior therapy imatinib combination CML drug Hydroxyurea and/or Anagrelide ; 4.Imatinib therapy start 12 month date original diagnosis ; 5.Unable tolerate imatinib 400mg ; 6.Previous treatment tyrosine kinase inhibitor except Glivec and/or CML therapy IFN , hydroxyurea , /or anagrelide ; 7.Myelotoxicity ≥ Grade 2 present time randomization , 8.Previously document T315I mutation ; 9.Impaired cardiac function include one : Long QT syndrome family history long QT syndrome Clinically significant rest brachycardia ( &lt; 50 bpm ) QTcF &gt; 450 msec screen ECG ( use QTcF formula ) . If QTc &gt; 450 electrolyte normal range , electrolyte correct patient rescreened QTc certify QTc &lt; 450 msec ; Myocardial infarction ≤ 12 month prior first dose study drug ; Other clinically significant heart disease ( e.g. , CHF , uncontrolled hypertension , unstable angina , significant ventricular atrial tachyarrhythmias ) 10 . Impairment GI function disease may significantly alter absorption study drug ; 11 . Treated strong CYP3A4 inhibitor either discontinue switched different medication prior start study drug ; 12.Currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug ; 13.History previous acute pancreatitis within one year study entry medical history chronic pancreatitis ; 14.Known cytopathologically confirm CNS 15.Women pregnant , breast feeding childbearing potential without negative urine pregnancy test screening . Female patient childbearing potential unwilling use effective contraceptive precaution throughout trial 3 month post trial end . Postmenopausal woman must ammenorrheic least 12 month consider nonchildbearing potential ; 16 . History another primary malignancy currently clinically significant currently require active intervention ; 17.Any clinically significant medical surgical condition , accord investigator ' discretion , preclude participation ; 18.Use investigational agent within 28 day prior enrollment ; 19.Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Chronic</keyword>
	<keyword>Myelogenous</keyword>
	<keyword>Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Phase</keyword>
	<keyword>Suboptimal Response</keyword>
</DOC>